CINRYZE Support

Not real patients.

Path to Independence^™ Self-Administration Training

Path to Independence^™ is a training program designed to help teach people with HAE, family members, and caregivers how to administer CINRYZE. The Path to Independence Program is available at no cost to eligible people prescribed CINRYZE.

A specially trained infusion nurse will:

Visit your home or another location agreed upon by you and your doctor
Work with you at a time that's convenient — including evenings and weekends
Show you how to prepare your CINRYZE dose
Train you on how to self-administer CINRYZE safely and correctly. Infusion nurses can also train caregivers and/or a family member

Once your nurse determines that you're ready to self-administer CINRYZE, you can take over administering your own CINRYZE doses.

Do not try to self-administer CINRYZE until a
healthcare professional has taught you or a caregiver how.

Want more information on self-administration training
with the Path to Independence™ Program?

Download the brochure

You might also be interested in:

Resource Library Sign Up for Information

ExpandClose Important Safety Information

You should not use CINRYZE if you have had life-threatening immediate hypersensitivity reactions, including anaphylaxis, to the product.

Tell your healthcare provider about all of your medical conditions, including if you have an indwelling catheter/access device in one of your veins; have a history of blood clots, heart disease, or stroke; or are taking birth control pills or androgens. Also tell your healthcare provider if you are pregnant or planning to become pregnant, or are breastfeeding or planning to breastfeed. It is not known if CINRYZE can harm your unborn baby, or if CINRYZE passes into your milk and if it can harm your baby.

Allergic reactions may occur with CINRYZE. Call your healthcare provider or get emergency support services right away if you have any of the following symptoms: wheezing, difficulty breathing, chest tightness, turning blue (look at lips and gums), fast heartbeat, swelling of the face, faintness, rash, hives.

Serious blood clots may occur with CINRYZE. Call your healthcare provider or get emergency support services right away if you have any of the following symptoms: pain and/or swelling of an arm or leg with warmth over the affected area, discoloration of an arm or leg, unexplained shortness of breath, chest pain or discomfort that worsens on deep breathing, unexplained rapid heart rate, numbness or weakness on one side of the body.

Because CINRYZE is made from human blood, it may carry a risk of transmitting infectious agents, e.g., viruses and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent.

The most common side effects seen with CINRYZE were headache, nausea, rash, and vomiting. These are not all the possible side effects of CINRYZE. Tell your healthcare provider about any side effect that bothers you or that does not go away. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

For additional safety information, please click here for Full Prescribing Information and discuss with your doctor.

You are encouraged to report negative side effects of prescription drugs to the FDA.

Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

©2024 Takeda Pharmaceuticals U.S.A., Inc., 500 Kendall Street, Cambridge, MA 02142. 1-877-TAKEDA-7 (1-877-825-3327). All rights reserved. TAKEDA^®, the TAKEDA Logo^® and the TAKEDA Patient Support Logo™ are registered trademarks of Takeda Pharmaceutical Company Limited. CINRYZE^® and the CINRYZE Logo^® are registered trademarks of Viropharma Biologics LLC.

Other Treatment Options

CINRYZE Support

Path to Independence^™ Self-Administration Training

Definition:

CINRYZE Support

Path to Independence™ Self-Administration Training

Definition:

Path to Independence^™ Self-Administration Training